NIH Seeks Approval to Keep Tracking Clinical Trial Data
Published Date: 2/19/2026
Notice
Summary
The National Institutes of Health (NIH) is asking for a 30-day public comment on their plan to keep and update a big list of clinical trials and their results. This affects researchers and medical folks who share trial info, helping everyone find trustworthy health study data. No big costs or changes are expected, but your feedback is welcome before the current approval expires on March 31, 2026.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
NIH Seeks 3-Year OMB Clearance
The NIH is asking OMB to approve the ClinicalTrials.gov information collection (OMB control number 0925-0586) for 3 years. The current approval expires on 03/31/2026, and the agency estimates total annualized respondent burden of 1,411,181 hours and says there are no costs to respondents other than their time.
Mandatory Registration and Results Rule Applies
The notice restates that 42 CFR part 11 requires registration and results submission for certain applicable clinical trials of drug, biological, and device products, whether or not the products are FDA approved, licensed, or cleared. Entities running those trials must register and submit results as required by the regulation.
Continued Public Access to Trial Data
NIH operates ClinicalTrials.gov to collect registration and results information to enhance patient enrollment and to track study progress for the benefit of public health. The registry is widely used by patients, physicians, and medical researchers and will continue to be maintained.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14964, Center for Scientific Review; Notice of Closed Meeting
The Center for Scientific Review is holding a closed virtual meeting on August 19, 2026, to review neuroscience career development grant applications. This meeting is private to protect sensitive info like trade secrets and personal details. Researchers applying for these grants should note the date, as funding decisions could impact their projects and careers.
Previous / Next Documents
Previous: 2026-03221, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in late March 2026 to review and decide on important research grant applications. These meetings protect private info and trade secrets while helping decide who gets funding for brain, cancer, and cell biology studies. Scientists and researchers applying for grants should note these dates as they impact funding decisions but don’t involve public attendance or extra costs.
Next: 2026-03223, Notice of Inventory Completion: University of Florida, Florida Museum of Natural History, Gainesville, FL
The University of Florida’s Florida Museum of Natural History has finished checking its collection of Native American human remains and related items from 24 Florida sites. They found 416 individuals and nearly 22,000 objects connected to Native tribes. Starting March 23, 2026, these remains and items can be returned to the tribes, making history and healing happen!